This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Sangamo BioSciences Announces Presentation Of Clinical Data From ZFP Therapeutic® For HIV/AIDS At ICAAC 2012

Stocks in this article: SGMO





RICHMOND, Calif., Sept. 10, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that data from its Phase 1 clinical programs to develop SB-728-T, a novel therapeutic approach designed to generate a "functional cure" for  HIV/AIDS, were presented at the 52 nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The meeting is being held in San Francisco from September 9-12, 2012. 

"The immunologic data presented at ICAAC have predictive implications for the success of this exciting new therapeutic approach to HIV and the realization of a 'functional cure' for the disease," commented Rafick-Pierre Sékaly,  Ph.D., Co-Director & Chief Scientific Officer, the Vaccine & Gene Therapy Institute of Florida (VGTI Florida), whose laboratory carried out the analysis.  "SB-728-T treatment results in an unprecedented and durable increase in CD4+ cells.  Importantly, our analysis shows that this is primarily due to the expansion of CD4+ T-cell types that are vital for the successful reconstitution of the immune system in HIV-infected individuals - the central and transitional memory cells."

"These data are very important because CD4 T-cells, especially memory T-cells, are precisely the cell type that we would want to protect and expand to enable HIV-infected individuals to control infections, and HIV, without antiretroviral drugs," added Dale Ando, M.D., Sangamo's vice president of therapeutic development and chief medical officer. "Our aim is to provide a protected reservoir of immune memory cells to replenish the cells killed by HIV and to generate an effective immune response against the virus and opportunistic infections. Central and transitional memory T-cells remember previously encountered foreign invaders, such as viruses or bacteria.  These cells can survive in the body for the individual's lifetime, and when they re-encounter the same antigen they reactivate, producing a faster and stronger immune response than the previous encounter. SB-728-T seems to both expand the total memory pool, and by CCR5 modification, protect a proportion of that pool from HIV entry, suggesting that SB-728 treatment has the potential to reconstitute and protect an effective and durable immune system in HIV-infected individuals."

SB-728-T is generated by ZFN-mediated modification of the gene encoding the CCR5 receptor in a patient's own T-cells, disrupting the expression of this key co-receptor for HIV entry and rendering the modified cells resistant to HIV infection.

1 of 5

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,614.81 +215.14 1.31%
S&P 500 1,941.28 +37.27 1.96%
NASDAQ 4,419.4780 +103.4040 2.40%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs